NeuroPace Analysts Fine-Tune Fair Value Price Target to $19.43 Per Share

NeuroPace's fair value price target has been revised from $17.13 to $19.43 per share, reflecting a fine-tuning of risk and revenue growth expectations rather than a dramatic new outlook. Analysts have refreshed their core assumptions with a slight adjustment in the discount rate and more conservative revenue growth expectations. The modest change in target implies caution and reservations around valuation and near-term risks, limiting price target movements without new information.